Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
Article
[키워드] addition
Administered
adverse effect
aluminum
applied
candidate vaccine
Combination
COVID-19
COVID-19 disease
COVID-19 pandemic
COVID-19 vaccine
CpG
cross-neutralize
cytokine
D614G variant
development
dominant
elicited
ENhance
health emergency
hydroxide
immunized
immunized mice
immunology
immunopathology
lentivirus
MERS-CoV
mice
Microbiology
mitigate
neutralizing antibody
prefusion
Prevent
pseudotyped
pseudovirus
reporter
S-2P
SARS-CoV-2 spike antigen
SARS-CoV-2 spike protein
secreted
sera
splenocyte
subunit
Support
Th1
the antibody
the spike protein
TLR9
Toll-like receptor
Treatment
two-dose regimen
Vaccine
was selected
wild-type SARS-CoV-2
[DOI] 10.1038/s41598-020-77077-z PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41598-020-77077-z PMC 바로가기 [Article Type] Article